Form 8-K

8-K — Nuvectis Pharma, Inc.

Accession: 0001104659-26-055264

Filed: 2026-05-05

Period: 2026-05-05

CIK: 0001875558

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — tm2613389d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2613389d1_ex99-1.htm)

GRAPHIC (tm2613389d1_ex99-1img01.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2613389d1_8k.htm · Sequence: 1

false

0001875558

2026-05-05

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported):

May 5, 2026

Nuvectis Pharma, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction

of Incorporation)

001-41264

(Commission File Number)

86-2405608

(IRS Employer Identification No.)

1 Bridge Plaza Suite 275

Fort Lee, NJ 07024

(Address of Principal Executive Offices)

(201) 614-3150

(Registrant’s telephone number, including

area code)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Securities registered pursuant to Section 12(b) of the

Exchange Act:

Title of Class

Trading Symbol(s)

Exchange Name

Common Stock

NVCT

Nasdaq Capital Market

Written communications pursuant to Rule 425 under the Securities Act.

Soliciting material pursuant to Rule 14a-12 under the Exchange Act.

Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02.

Results of Operations and Financial Condition.

On May 5, 2026, Nuvectis

Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the first quarter ended March

31, 2026. A copy of such press release is being furnished as Exhibit 99.1 to this report.

The information, including

Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities

Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Form 8-K shall not

be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall otherwise be expressly set

forth by specific reference in such filing.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

The following exhibit is furnished herewith:

Exhibit

Number

Description

99.1

Press release issued by Nuvectis Pharma, Inc., dated May 5, 2026.

104

Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned

hereunto duly authorized.

Nuvectis Pharma, Inc.

(Registrant)

Date: May 5, 2026

By:

/s/ Ron Bentsur

Ron Bentsur

Chairman, Chief Executive Officer and President

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2613389d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results

and Business Highlights

· NXP900 Phase 1b clinical program continues to enroll patients at select

sites in the US

· NXP900 preclinical presentations at the 2026 American Association for Cancer

Research (“AACR”) Annual Meeting” further support the clinical development strategy

May 5, 2026, Fort Lee, NJ - Nuvectis Pharma, Inc.

(NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development

of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today reported its financial

results for the first quarter of 2026 and provided an update on recent business progress.

Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented,

“2026 is off to a good start for Nuvectis as we advance the NXP900 Phase 1b clinical program which continues to enroll patients

at top sites in the US in both the monotherapy and combination arms of the program.” Mr. Bentsur added, “At this year’s

AACR conference held last month, we provided preclinical data supporting the use of NXP900 in combination with sotorasib, a RAS inhibitor,

in non-small cell lung cancer (NSCLC). The combination demonstrated clear synergy both in sotorasib-sensitive and sotorasib-resistant

NSCLC models.”

Mr. Bentsur concluded, “We are excited for what’s ahead

in 2026 and expect a preliminary data readout from the NXP900 Phase 1b study in the summer. We continue to operate with financial discipline

and remain focused on achieving key clinical development milestones in our NXP900 program in 2026 and beyond.”

First Quarter 2026 Financial Results

Cash and cash equivalents were $25.1 million as of March 31, 2026,

compared to $31.6 million as of December 31, 2025.

The Company's net loss was $6.1 million for the three months ended

March 31, 2026, compared to $5.3 million for the three months ended March 31, 2025, an increase of $0.8 million. Non-cash stock-based

compensation was $1.9 million for the three months ended March 31, 2026 compared to $1.4 million for the three months ended March 31,

2025.

Research and development expenses were $4.1 million for the three months

ended March 31, 2026, compared to $3.7 million for the three months ended March 31, 2025, an increase of $0.4 million. The increase was

primarily driven by a $0.4 million increase in manufacturing costs, a $0.3 million increase in employee compensation and benefits, and

a $0.2 million increase in clinical trial expenses, partially offset by a $0.5 million reduction in license fees and other professional

services.

General and administrative expenses were $2.2 million for the three

months ended March 31, 2026, compared to $1.9 million for the three months ended March 31, 2025, an increase of $0.3 million. The increase

was primarily driven by a $0.2 million increase in professional and consulting services related to public company expenses and a $0.1

million increase in employee compensation and benefits.

Finance income was $0.2 million for the three months ended March 31,

2026 and 2025.

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the

development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is

developing NXP900, a clinical-stage drug candidate. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases (SFK), including

SRC and YES1. Its unique mechanism of action enables inhibition of both the catalytic and scaffolding functions of the SRC kinase, providing

comprehensive shutdown of the signaling pathway. NXP900 has completed a Phase 1a dose escalation study, a drug-drug interaction study

in healthy volunteers and the Phase 1b program is ongoing.

Forward Looking Statements

This press release contains "forward-looking

statements" within the meaning of the U.S. federal securities laws, which are subject to substantial risks and uncertainties. All

statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking

statements contained in this press release may be identified by the use of words such as "anticipate", "believe",

"contemplate", "could", "estimate", "expect", "intend", "seek", "may",

"might", "plan", "potential", "predict", "project", "target", "aim",

"should", "will", "would", or the negative of these words or other similar expressions, although not all

forward-looking statements contain these words. Forward looking statements are based on Nuvectis Pharma, Inc.'s current expectations and

interpretations of data and information available, including preclinical and clinical safety, pharmacokinetics, pharmacodynamics, and

efficacy data generated to date for NXP900 and the timing and safety and efficacy data expectations for the monotherapy and combination

components of the NXP900 Phase 1b program and estimates and projections regarding our financial condition. The outcomes of the events

described in these forward-looking statements are subject to inherent uncertainties, risks, assumptions, market and other conditions,

and other factors that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events

that may not prove to be accurate. These and other risks and uncertainties may also be subject to market and other conditions and described

more fully in the section titled "Risk Factors" in our 2025 Form 10-K and our other public filings with the U.S. Securities

and Exchange Commission ("SEC"). However, these risks are not exhaustive and new risks and uncertainties emerge from time to

time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward looking statements

contained in this press release or other filings with the SEC. Any forward-looking statements contained in this press release speak only

as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions

to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances

on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking

statements contained in the Private Securities Litigation Reform Act of 1995.

Company Contact:

Ron Bentsur

Chairman, Chief Executive Officer and President

rbentsur@nuvectis.com

Media Relations Contact:

Kevin Gardner

LifeSci Advisors

kgardner@lifesciadvisors.com

NUVECTIS PHARMA, INC.

BALANCE SHEET

(USD in thousands, except per share and share

amounts)

March 31,

December 31,

2026

2025

Assets

CURRENT ASSETS

Cash and cash equivalents

$ 25,130

$ 31,634

Other current assets

268

TOTAL CURRENT ASSETS

25,398

31,709

TOTAL ASSETS

$ 25,398

$ 31,709

Liabilities and Shareholders’ Equity

CURRENT LIABILITIES

Accounts payable

$ 4,695

$ 6,274

Accrued liabilities

115

Employee compensation and benefits

6,447

6,907

TOTAL CURRENT LIABILITIES

11,178

13,296

TOTAL LIABILITIES

11,178

13,296

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS’ EQUITY

Common Shares, $0.00001 par value – 60,000,000 shares authorized as of March 31, 2026, and December 31, 2025, 26,525,533, and 25,676,798 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively

Additional paid in capital

119,957

118,100

Accumulated deficit

(105,737 )

(99,687 )

TOTAL SHAREHOLDERS’ EQUITY

14,220

18,413

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

$ 25,398

$ 31,709

* Represents an amount lower than $1,000 USD.

NUVECTIS PHARMA, INC.

STATEMENT OF OPERATIONS

(USD in thousands, except per share and share

amounts)

Three Months Ended March 31

2026

2025

OPERATING EXPENSES

Research and development

$ 4,106

$ 3,680

General and administrative

2,154

1,888

OPERATING LOSS

(6,260 )

(5,568 )

Finance income

210

236

NET LOSS

$ (6,050 )

$ (5,332 )

TOTAL NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS

$ (6,050 )

$ (5,332 )

BASIC AND DILUTED NET LOSS PER COMMON SHARE OUTSTANDING

$ (0.26 )

$ (0.27 )

Basic and diluted weighted average number of common shares outstanding

23,414,475

19,937,507

GRAPHIC

Filename: tm2613389d1_ex99-1img01.jpg · Sequence: 6

Binary file (21557 bytes)

Download tm2613389d1_ex99-1img01.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

May 05, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

May 05, 2026

Entity File Number

001-41264

Entity Registrant Name

Nuvectis Pharma, Inc.

Entity Central Index Key

0001875558

Entity Tax Identification Number

86-2405608

Entity Incorporation, State or Country Code

Entity Address, Address Line One

1 Bridge Plaza Suite 275

Entity Address, City or Town

Fort Lee

Entity Address, State or Province

Entity Address, Postal Zip Code

07024

City Area Code

201

Local Phone Number

614-3150

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock

Trading Symbol

NVCT

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration